KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Net Income (2016 - 2025)

Historic Net Income for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to -$2.0 million.

  • Edwards Lifesciences' Net Income fell 10007.39% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.7 million, marking a year-over-year decrease of 9907.25%. This contributed to the annual value of $2.8 billion for FY2024, which is 144609.81% up from last year.
  • Edwards Lifesciences' Net Income amounted to -$2.0 million in Q3 2025, which was down 10007.39% from -$4.4 million recorded in Q2 2025.
  • Edwards Lifesciences' 5-year Net Income high stood at $2.7 billion for Q3 2024, and its period low was -$7.2 million during Q1 2025.
  • In the last 5 years, Edwards Lifesciences' Net Income had a median value of $54.1 million in 2023 and averaged $303.5 million.
  • Its Net Income has fluctuated over the past 5 years, first surged by 544774.59% in 2024, then plummeted by 54000.0% in 2025.
  • Over the past 5 years, Edwards Lifesciences' Net Income (Quarter) stood at $335.3 million in 2021, then plummeted by 40.2% to $200.5 million in 2022, then tumbled by 81.75% to $36.6 million in 2023, then rose by 7.38% to $39.3 million in 2024, then plummeted by 105.09% to -$2.0 million in 2025.
  • Its Net Income was -$2.0 million in Q3 2025, compared to -$4.4 million in Q2 2025 and -$7.2 million in Q1 2025.